John Green (Author, YouTuber, etc), alongside various NGOs, has started a campaign to pressure Johnson and Johnson to allow generic versions of Sirturo (bedaquiline), a drug used to treat multi-drug-resistant tuberculosis.

John Green (citing NGO sources) claims that allowing generic bedaquiline will reduce the cost by 60%, allowing up to 6 million people to receive treatment over the next 4 years, many of whom will die without that treatment.

Johnson and Johnson tweeted a response:

Which was tagged with a community note with MSF data to contradict their claims.

I'm open to feedback on objective resolution criteria for this market. Mainly I'll rely on reputable news sources, but I imagine there's lots of legal gray area that could come up here that I'm entirely unqualified to interpret. In general, if health NGOs and John Green seem pleased with the outcome, I'd lean towards resolving "Yes", otherwise "No". Resolution is based on announcement not implemention (mostly because the latter seems way hazier to piece through exactly what it means)